In our study, for locally advanced or metastatic esophageal squamous cell carcinoma, the combination of sintilimab and chemotherapy was cost-effective in the total population and in PD-L1-positive population at a WTP threshold of $37,653. Here, CD274 is linked to esophageal squamous cell carcinoma.